Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
| ▸ | TUBB | P07437 | 1/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5345714 | 0.86 | LMNA (0.65) | NPC1RAB9ASMN1; SMN2PKMMAOB | |
| SCHEMBL5200654 | 0.84 | LMNA (0.52) | NPC1RAB9ASMN1; SMN2PKMMAOB | |
| SCHEMBL9719979 | 0.84 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2PKMMAOB | |
| SCHEMBL5035998 | 0.83 | LMNA (0.54) | NPC1SMN1; SMN2ADORA2ALMNACYP3A4 | |
| SCHEMBL29006649 | 0.80 | ABL1 (0.56) | NPC1RAB9ASMN1; SMN2PKMMAOB | |
| SCHEMBL11549633 | 0.80 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2PKMMAOB | |
| SCHEMBL11400518 | 0.80 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2PKMMAOB | |
| SCHEMBL544177 | 0.79 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5037713 | 0.79 | LCK (0.56) | NPC1RAB9ASMN1; SMN2ADORA2ALMNA | |
| SCHEMBL204726 | 0.78 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2PKMMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-08-14 | — | — | US | disclosed |
| EP-1934187-A1 | NOVEL BENZIMIDAZOLE AND BENZOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | Aventis Pharma S.A. (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007036630-A1 | NOVEL BENZIMIDAZOLE AND BENZOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | MET, KIT, MERTK | NPC1 508/4885RAB9A 3640/4885SMN1; SMN2 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.